Merck Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor September 28, 2022
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib September 28, 2022
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines September 28, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
Pivotal Ph 3 Trial of Olvi-Vec for the treatment of Platinum-Resistant/Refractory Ovarian Cancer initiated September 28, 2022
Enrollment of the Ph 1/2 OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer completed September 28, 2022
Adjuvant Treatment with Opdivo Demonstrated Statistically Significant Improvement in RFS in Patients with Stage IIB/C Melanoma in the CheckMate-76K Trial September 28, 2022
Results from Ph 2 trial of zevorcabtagene autoleucel Ph 1b/2 study in RRMM patients announced September 28, 2022
Recommended Dose for Planned Registrational Study of NBTXR3 Plus Anti-PD-1 for Patients With mSCCHN Resistant to Prior Immunotherapy Established September 28, 2022
TUKYSA® (tucatinib) + Trastuzumab combo Granted Priority Review by FDA for Previously Treated HER2+ve Metastatic CRC September 28, 2022
Applications Submitted For Rubraca® Label Expansion In The US And EU As 1L Maintenance Treatment In Advanced Ovarian Cancer Patients September 28, 2022
Positive CHMP Opinion for BRUKINSA® (zanubrutinib) for the Treatment of Adults with MZL September 28, 2022
Yescarta® Gets Positive CHMP Opinion For Use In 2L DLBCL And High-Grade B-Cell Lymphoma September 28, 2022
Oncologic Drugs Advisory Committee to review Zejula overall survival data from the NOVA Ph 3 trial in recurrent ovarian cancer September 28, 2022
FDA Approves Retevmo® (selpercatinib) for Adults with Advanced or Metastatic Solid Tumors with a RET Gene Fusion, Regardless of Type September 28, 2022
European Commission approves Opdualag (nivolumab + relatlimab) for the Treatment of Unresectable or Metastatic Melanoma with Tumor Cell PD-L1 Expression < 1% September 28, 2022
Lynparza approved in China as 1L maintenance treatment with bevacizumab for HRD+ve advanced ovarian cancer September 28, 2022
